
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte is well-positioned for growth in the biotech industry due to its diverse portfolio of small-molecule drugs, strong partnerships with major pharmaceutical companies, and successful launches of its leading drug Jakafi. With a promising pipeline of oncology and dermatology programs, the company has the potential to expand its market presence and drive future revenue growth. The recent positive CHMP opinion for Opzelura in atopic dermatitis and potential for a simpler subsequent presentation for subQ delivery of Jakafi through the ENHANZE technology also add to the company's positive outlook. With solid financials and a defined growth strategy, Incyte is a strong investment opportunity in the biotech sector.
Bears say
Incyte is facing numerous valuation and risk concerns as it operates in the highly competitive pharmaceutical industry. Despite having a strong partnership with Novartis and a diverse portfolio of marketed drugs, the lack of clarity on the timelines, bioavailability profile and economics of their ENHANZE formulation raise concerns for their long-term sustainability. Additionally, potential failures in ongoing clinical programs and risks related to efficacy, safety, and commercial costs are also major red flags for investors.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares